{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:50:46Z","timestamp":1790707846583,"version":"4.1.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Allecra Therapeutics SAS, France"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Enmetazobactam, formerly AAI101, is a novel penicillanic acid sulfone extended-spectrum \u03b2-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime has entered clinical trials to assess safety and efficacy in patients with complicated urinary tract infections.<\/jats:p>","DOI":"10.1128\/aac.00514-19","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T10:51:07Z","timestamp":1555411867000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":100,"title":["<i>In Vitro<\/i>\n            Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014\u20132015"],"prefix":"10.1128","volume":"63","author":[{"given":"Ian","family":"Morrissey","sequence":"first","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Magnet","sequence":"additional","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hawser","sequence":"additional","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Knechtle","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"e_1_3_2_4_2","volume-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_2_5_2","volume-title":"Healthcare-associated infections acquired in intensive care units: annual epidemiological report, 2016","author":"European Centre for Disease Prevention and Control","year":"2017","unstructured":"European Centre for Disease Prevention and Control. 2017. Healthcare-associated infections acquired in intensive care units: annual epidemiological report, 2016. ECDC, Stockholm, Sweden."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555819316"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw102"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01076-18"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717295115"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx181"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01195-18"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.6.805"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1154538"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens4030620"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00033-15"},{"key":"e_1_3_2_18_2","volume-title":"Identifier NCT03687255: safety and efficacy study of cefepime-AAI101 in the treatment of complicated urinary tract infections","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov. 2018. Identifier NCT03687255: safety and efficacy study of cefepime-AAI101 in the treatment of complicated urinary tract infections. National Library of Medicine, Bethesda, MD."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01377.x"},{"key":"e_1_3_2_20_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing; 29th ed. CLSI supplement M100. CLSI, Wayne, PA.","edition":"29"},{"key":"e_1_3_2_21_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 9.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2019","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters, version 9.0. EUCAST, Basel, Switzerland."},{"key":"e_1_3_2_22_2","volume-title":"Sanford guide to antimicrobial therapy","author":"Gilbert DN","year":"2018","unstructured":"Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Pavia A. 2018. Sanford guide to antimicrobial therapy, 48th ed. Antimicrobial Therapy, Inc, Sperryville, VA.","edition":"48"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110655"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix893"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw282"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-015-0055-6"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky168"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_3_2_29_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A10, 10th ed. CLSI, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_30_2","volume-title":"Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design","author":"Huband MD","year":"2018","unstructured":"Huband MD, Shapiro S, Fiedler KA, Flamm RK. 2018. Cefepime-AAI101 and cefepime MIC quality control ranges using a CLSI M23-A5 multi-laboratory study design, 28th ed, poster P2492. ECCMID, Madrid, Spain.","edition":"28"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05186-14"},{"key":"e_1_3_2_32_2","volume-title":"Bacterial antimicrobial resistance reference gene database","author":"National Center for Biotechnology Information","year":"2019","unstructured":"National Center for Biotechnology Information. 2019. Bacterial antimicrobial resistance reference gene database. NCBI, Bethesda, MD. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA313047."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00514-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00514-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:35:15Z","timestamp":1645479315000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00514-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1128\/AAC.00514-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00514-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2019-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00514-19"}}